Associated Genetic Biomarkers
DNAJB1 is altered in 1.00% of all cancers with high grade ovarian serous adenocarcinoma, breast invasive ductal carcinoma, fibrolamellar carcinoma, colon adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in DNAJB1 are DNAJB1 Amplification (0.40%), DNAJB1-PRKACA Fusion (0.09%), DNAJB1 Loss (0.04%), DNAJB1 E43del (0.01%), and DNAJB1 E62K (0.01%) .
DNAJB1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains DNAJB1 status as an inclusion criterion, 1 is phase 1 (1 open).
The most frequent alteration to serve as an inclusion eligibility criterion is DNAJB1-PRKACA Fusion .
Significance of DNAJB1 in Diseases
Fibrolamellar Carcinoma +
DNAJB1 is altered in 89.29% of fibrolamellar carcinoma patients .
DNAJB1 is an inclusion criterion in 1 clinical trial for fibrolamellar carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DNAJB1 status and fibrolamellar carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.